Web Exclusives

For the treatment of patients with HR-positive/HER2-negative metastatic breast cancer, targeting CDK4/6 represents a novel, effective, and safe therapeutic approach in combination with hormone therapy. Read More ›

CDK4/6 inhibitors were associated with improved outcomes in HR-positive/HER2-negative advanced metastatic breast cancer. Read More ›

Study results suggest the potential of clinical development of estrogen receptor, CDK4/6, and AKT co-targeting strategies after progression on a CDK4/6 inhibitor and endocrine therapy combination, and in tumors showing high phospho-AKT levels. Read More ›

CheckMate 649 study results demonstrate that nivolumab combined with chemotherapy has an acceptable safety profile and improves survival outcomes in patients with advanced gastric/esophageal cancer. Read More ›

Japanese study data demonstrate second-line pembrolizumab improved overall survival with an acceptable safety profile compared with chemotherapy in patients with advanced esophageal cancer. Read More ›

An expert panel released recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma. Read More ›

Nivolumab added to either ipilimumab or chemotherapy improved overall survival in patients with advanced esophageal squamous-cell carcinoma, according to data from the CheckMate-648 study. Read More ›

A comprehensive analysis of immune checkpoints in gastric adenocarcinoma found that ICOSLG and CD70 are associated with immune infiltration and may potentially serve as prognostic biomarkers. Read More ›

Phase 2 study results of second-line trastuzumab deruxtecan use in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer revealed an antitumor response. Read More ›

Researchers reported that molecular testing in patients with non–small-cell lung cancer aged ≥70 years is performed at the same proportions as in younger patients. Read More ›